;PMID: 195583
;source_file_967.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:41..118] = [t:41..118]
;2)section:[e:122..170] = [t:122..170]
;3)sentence:[e:174..274] = [t:174..274]
;4)sentence:[e:275..351] = [t:275..351]
;5)sentence:[e:352..552] = [t:352..552]
;6)sentence:[e:553..698] = [t:553..698]
;7)sentence:[e:699..840] = [t:699..840]
;8)sentence:[e:841..1044] = [t:841..1044]
;9)sentence:[e:1045..1163] = [t:1045..1163]
;10)sentence:[e:1164..1345] = [t:1164..1345]
;11)section:[e:1349..1392] = [t:1349..1392]

;section 0 Span:0..35
;Biochem J. 1977 Apr 15;164(1):83-9.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..10] J.) (CD:[11..15] 1977)
        (NNP:[16..19] Apr) (CD:[20..22] 15) (CD:[22..27] ;164-LRB-)
        (CD:[27..28] 1) (-RRB-:[28..29] -RRB-) (CD:[29..32] :83)
        (HYPH:[32..33] -) (CD:[33..35] 9.)))

;sentence 1 Span:41..118
;Feedback regulation of vitamin D metabolism by
;1,25-dihydroxycholecalciferol.
;[64..73]:substance:"vitamin D"
;[88..117]:substance:"1,25-dihydroxycholecalciferol"
(SENT
  (NP-HLN
    (NP (NN:[41..49] Feedback) (NN:[50..60] regulation))
    (PP (IN:[61..63] of)
      (NP
        (NML (NN:[64..71] vitamin) (NN:[72..73] D))
        (NN:[74..84] metabolism)))
    (PP (IN:[85..87] by)
      (NP (NN:[88..117] 1,25-dihydroxycholecalciferol)))
    (.:[117..118] .)))

;section 2 Span:122..170
;Colston KW, Evans IM, Spelsberg TC, MacIntyre I.
(SEC
  (FRAG (NNP:[122..129] Colston) (NNP:[130..132] KW) (,:[132..133] ,)
        (NNP:[134..139] Evans) (NNP:[140..142] IM) (,:[142..143] ,)
        (NNP:[144..153] Spelsberg) (NNP:[154..156] TC) (,:[156..157] ,)
        (NNP:[158..167] MacIntyre) (NNP:[168..170] I.)))

;sentence 3 Span:174..274
;Many factors influence the production of 1,25(OH)2D3 
;(1,25-dihydroxycholecalciferol) by the kidney.
;[215..226]:substance:"1,25(OH)2D3"
;[229..258]:substance:"1,25-dihydroxycholecalciferol"
(SENT
  (S
    (NP-SBJ (JJ:[174..178] Many) (NNS:[179..186] factors))
    (VP (VBP:[187..196] influence)
      (NP
        (NP (DT:[197..200] the) (NN:[201..211] production))
        (PP (IN:[212..214] of)
          (NP
            (NP (NN:[215..226] 1,25-LRB-OH-RRB-2D3))
            (NP (-LRB-:[228..229] -LRB-)
                (NN:[229..258] 1,25-dihydroxycholecalciferol)
                (-RRB-:[258..259] -RRB-))))
        (PP (IN:[260..262] by)
          (NP (DT:[263..266] the) (NN:[267..273] kidney)))))
    (.:[273..274] .)))

;sentence 4 Span:275..351
;One important factor seems to be  feedback regulation by 1,25(OH)2D3 itself.
;[332..343]:substance:"1,25(OH)2D3"
(SENT
  (S
    (NP-SBJ-1 (CD:[275..278] One) (JJ:[279..288] important)
              (NN:[289..295] factor))
    (VP (VBZ:[296..301] seems)
      (S
        (NP-SBJ-1 (-NONE-:[301..301] *))
        (VP (TO:[302..304] to)
          (VP (VB:[305..307] be)
            (NP-PRD
              (NP (NN:[309..317] feedback) (NN:[318..328] regulation))
              (PP (IN:[329..331] by)
                (NP
                  (NP (NN:[332..343] 1,25-LRB-OH-RRB-2D3))
                  (NP (PRP:[344..350] itself)))))))))
    (.:[350..351] .)))

;sentence 5 Span:352..552
;Administration of 1,25(OH)2D3 to  vitamin D-deficient chicks abolishes renal 
;25(OH)D3(25-hydroxycholecalciferol)1-hydroxylase activity and induces the 
;appearance of 25(OH)D3 24-hydroxylase activity.
;[370..381]:substance:"1,25(OH)2D3"
;[386..395]:substance:"vitamin D"
;[430..478]:substance:"25(OH)D3(25-hydroxycholecalciferol)1-hydroxylase"
;[519..542]:substance:"25(OH)D3 24-hydroxylase"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[352..366] Administration))
      (PP (IN:[367..369] of)
        (NP (NN:[370..381] 1,25-LRB-OH-RRB-2D3)))
      (PP (TO:[382..384] to)
        (NP
          (ADJP
            (NML (NN:[386..393] vitamin) (NN:[394..395] D))
            (HYPH:[395..396] -) (JJ:[396..405] deficient))
          (NNS:[406..412] chicks))))
    (VP
      (VP (VBZ:[413..422] abolishes)
        (NP (JJ:[423..428] renal)
            (NN:[430..478] 25-LRB-OH-RRB-D3-LRB-25-hydroxycholecalciferol-RRB-1-hydroxylase)
            (NN:[479..487] activity)))
      (CC:[488..491] and)
      (VP (VBZ:[492..499] induces)
        (NP
          (NP (DT:[500..503] the) (NN:[505..515] appearance))
          (PP (IN:[516..518] of)
            (NP
               (NN:[519..527] 25-LRB-OH-RRB-D3) (NN:[528..542] 24-hydroxylase)
              (NN:[543..551] activity))))))
    (.:[551..552] .)))

;sentence 6 Span:553..698
;It is likely that these effects  are mediated via a nuclear effect, as they
;are prevented by pretreatment with  actinomycin D and alpha-amanitin.
;[665..678]:substance:"actinomycin D"
;[683..697]:substance:"alpha-amanitin"
(SENT
  (S
    (NP-SBJ
      (NP (PRP:[553..555] It))
      (SBAR-3 (-NONE-:[555..555] *EXP*)))
    (VP (VBZ:[556..558] is)
      (ADJP-PRD (JJ:[559..565] likely))
      (SBAR-3 (IN:[566..570] that)
        (S
          (NP-SBJ-2 (DT:[571..576] these) (NNS:[577..584] effects))
          (VP (VBP:[586..589] are)
            (VP (VBN:[590..598] mediated)
              (NP-2 (-NONE-:[598..598] *))
              (PP (IN:[599..602] via)
                (NP (DT:[603..604] a) (JJ:[605..612] nuclear)
                    (NN:[613..619] effect)))))))
      (,:[619..620] ,)
      (SBAR-ADV (IN:[621..623] as)
        (S
          (NP-SBJ-1 (PRP:[624..628] they))
          (VP (VBP:[629..632] are)
            (VP (VBN:[633..642] prevented)
              (NP-1 (-NONE-:[642..642] *))
              (PP-MNR (IN:[643..645] by)
                (NP
                  (NP (NN:[646..658] pretreatment))
                  (PP (IN:[659..663] with)
                    (NP
                      (NP (NN:[665..676] actinomycin) (NN:[677..678] D))
                      (CC:[679..682] and)
                      (NP (NN:[683..697] alpha-amanitin)))))))))))
    (.:[697..698] .)))

;sentence 7 Span:699..840
;Further, 1,25(OH)2D3 has a marked effect on  gene transcription in the kidney
;cell, as assessed by measurement of RNA  polymerase activities.
;[708..719]:substance:"1,25(OH)2D3"
;[813..828]:substance:"RNA  polymerase"
(SENT
  (S
    (ADVP (RB:[699..706] Further))
    (,:[706..707] ,)
    (NP-SBJ (NN:[708..719] 1,25-LRB-OH-RRB-2D3))
    (VP (VBZ:[720..723] has)
      (NP
        (NP (DT:[724..725] a) (JJ:[726..732] marked) (NN:[733..739] effect))
        (PP (IN:[740..742] on)
          (NP (NN:[744..748] gene) (NN:[749..762] transcription))))
      (PP-LOC (IN:[763..765] in)
        (NP (DT:[766..769] the) (NN:[770..776] kidney) (NN:[777..781] cell)))
      (,:[781..782] ,)
      (SBAR-ADV (IN:[783..785] as)
        (S
          (NP-SBJ-1 (-NONE-:[785..785] *))
          (VP (VBN:[786..794] assessed)
            (NP-1 (-NONE-:[794..794] *))
            (PP-MNR (IN:[795..797] by)
              (NP
                (NP (NN:[798..809] measurement))
                (PP (IN:[810..812] of)
                  (NP
                    (NML (NN:[813..816] RNA) (NN:[818..828] polymerase))
                    (NNS:[829..839] activities)))))))))
    (.:[839..840] .)))

;sentence 8 Span:841..1044
;RNA polymerase I and II activities are 80-90% inhibited  by 12.5nmol of
;1,25(OH)2D3 within 30min of subcutaneous administration,  indicating an
;immediate and massive decrease in total gene transcription.
;[841..857]:substance:"RNA polymerase I"
;[841..855]...[862..864]:substance:"RNA polymerase"..."II"
;[880..886]:quantitative-value:"80-90%"
;[901..905]:quantitative-value:"12.5"
;[905..909]:quantitative-units:"nmol"
;[913..924]:substance:"1,25(OH)2D3"
;[932..934]:quantitative-value:"30"
;[934..937]:quantitative-units:"min"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NML
          (NML-3 (NN:[841..844] RNA))
          (NML-4 (NN:[845..855] polymerase))
          (CD:[856..857] I))
        (NML-2 (-NONE-:[857..857] *P*)))
      (CC:[858..861] and)
      (NP
        (NML
          (NML-3 (-NONE-:[861..861] *P*))
          (NML-4 (-NONE-:[861..861] *P*))
          (CD:[862..864] II))
        (NML-2 (NNS:[865..875] activities))))
    (VP (VBP:[876..879] are)
      (NP-EXT
        (QP (CD:[880..882] 80) (HYPH:[882..883] -) (CD:[883..885] 90))
        (NN:[885..886] %))
      (VP (VBN:[887..896] inhibited)
        (NP-1 (-NONE-:[896..896] *))
        (PP (IN:[898..900] by)
          (NP-LGS
            (NP (CD:[901..905] 12.5) (NN:[905..909] nmol))
            (PP (IN:[910..912] of)
              (NP (NN:[913..924] 1,25-LRB-OH-RRB-2D3)))))
        (PP-TMP (IN:[925..931] within)
          (NP
            (NP (CD:[932..934] 30) (NN:[934..937] min))
            (PP (IN:[938..940] of)
              (NP (JJ:[941..953] subcutaneous) (NN:[954..968] administration)))))
        (,:[968..969] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[969..969] *))
          (VP (VBG:[971..981] indicating)
            (NP (DT:[982..984] an)
              (ADJP (JJ:[985..994] immediate) (CC:[995..998] and)
                    (JJ:[999..1006] massive))
              (NN:[1007..1015] decrease))
            (PP (IN:[1016..1018] in)
              (NP (JJ:[1019..1024] total) (NN:[1025..1029] gene)
                  (NN:[1030..1043] transcription)))))))
    (.:[1043..1044] .)))

;sentence 9 Span:1045..1163
;By 4h  RNA polymerase II activity has returned to control values, but RNA
;polymerase I  activity is markedly enhanced.
;[1048..1049]:quantitative-value:"4"
;[1049..1050]:quantitative-units:"h"
;[1052..1069]:substance:"RNA polymerase II"
;[1115..1131]:substance:"RNA polymerase I"
(SENT
  (S
    (S
      (PP-TMP (IN:[1045..1047] By)
        (NP (CD:[1048..1049] 4) (NN:[1049..1050] h)))
      (NP-SBJ
        (NML (NN:[1052..1055] RNA) (NN:[1056..1066] polymerase)
             (CD:[1067..1069] II))
        (NN:[1070..1078] activity))
      (VP (VBZ:[1079..1082] has)
        (VP (VBN:[1083..1091] returned)
          (PP (TO:[1092..1094] to)
            (NP (NN:[1095..1102] control) (NNS:[1103..1109] values))))))
    (,:[1109..1110] ,) (CC:[1111..1114] but)
    (S
      (NP-SBJ-1
        (NML (NN:[1115..1118] RNA) (NN:[1119..1129] polymerase)
             (CD:[1130..1131] I))
        (NN:[1133..1141] activity))
      (VP (VBZ:[1142..1144] is)
        (ADVP (RB:[1145..1153] markedly))
        (VP (VBN:[1154..1162] enhanced)
          (NP-1 (-NONE-:[1162..1162] *)))))
    (.:[1162..1163] .)))

;sentence 10 Span:1164..1345
;These results are consistent with the view that  regulation of
;cholecalciferol metabolism in the kidney is associated with an  effect of the
;active metabolite on the kidney nucleus.
;[1227..1242]:substance:"cholecalciferol"
;[1312..1322]:substance:"metabolite"
(SENT
  (S
    (NP-SBJ (DT:[1164..1169] These) (NNS:[1170..1177] results))
    (VP (VBP:[1178..1181] are)
      (ADJP-PRD (JJ:[1182..1192] consistent)
        (PP (IN:[1193..1197] with)
          (NP (DT:[1198..1201] the) (NN:[1202..1206] view)
            (SBAR (IN:[1207..1211] that)
              (S
                (NP-SBJ-1
                  (NP (NN:[1213..1223] regulation))
                  (PP (IN:[1224..1226] of)
                    (NP (NN:[1227..1242] cholecalciferol)
                        (NN:[1243..1253] metabolism)))
                  (PP-LOC (IN:[1254..1256] in)
                    (NP (DT:[1257..1260] the) (NN:[1261..1267] kidney))))
                (VP (VBZ:[1268..1270] is)
                  (VP (VBN:[1271..1281] associated)
                    (NP-1 (-NONE-:[1281..1281] *))
                    (PP-CLR (IN:[1282..1286] with)
                      (NP
                        (NP (DT:[1287..1289] an) (NN:[1291..1297] effect))
                        (PP (IN:[1298..1300] of)
                          (NP (DT:[1301..1304] the) (JJ:[1305..1311] active)
                              (NN:[1312..1322] metabolite)))
                        (PP (IN:[1323..1325] on)
                          (NP (DT:[1326..1329] the) (NN:[1330..1336] kidney)
                              (NN:[1337..1344] nucleus)))))))))))))
    (.:[1344..1345] .)))

;section 11 Span:1349..1392
;PMID: 195583 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1349..1353] PMID) (::[1353..1354] :) (CD:[1355..1361] 195583)
        (IN:[1362..1363] -LSB-) (NNP:[1363..1369] PubMed) (HYPH:[1370..1371] -)
        (JJ:[1372..1379] indexed) (IN:[1380..1383] for)
        (NNP:[1384..1392] MEDLINE-RSB-)))
